Compare TG Therapeutics Inc (TGTX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wells Fargo & Co — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Wells Fargo & Co trades at $90 (market cap $265.99B). The key difference: Wells Fargo & Co is far larger — about 31.2× TG Therapeutics Inc's market cap, and Wells Fargo & Co pays a 2.27% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WFC | |
|---|---|---|
Market Cap | $8.53B | $265.99B |
Sector | Health | Financials |
52-Week High | $59.06 | $96.40 |
52-Week Low | $26.94 | $73.42 |
Enterprise Value | $8.74B | — |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Wells Fargo (WFC) trades at $87.98, down 2.21% on the day, amid mixed earnings performance but strong profitability trends. The stock shows a bullish technical signal with support near $87 and resistance at $89, while fundamentals reveal a P/E of 12.78 and net income margin of 25.97% for 2025. Recent news highlights CEO Charlie Scharf's focus on dealmaking and a push to expand wealth management, with institutional buying activity noted in August 2026 filings.
Outlook remains cautiously optimistic with a consensus price target of $97.64, implying 11% upside, supported by improved return on tangible common equity and dividend payments. Risks include volatile cash flows, regulatory scrutiny, and interest rate sensitivity. Analyst consensus is balanced with 45% buy ratings, but recent earnings misses warrant monitoring execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
